INDEX 823
anal sac
adenocarcinoma, 170–171
disorders, 169–171,171–172
expression of contents, 170, 171
impaction, 169, 170,171–172
infection/abscessation, 169, 170, 172
neoplasia, 169
anal sacculitis, 169, 171
anaplastic carcinoma or sarcoma, 384
Ancefseecefazolin sodium
Ancobonseeflucytosine
Andro-Cypseetestosterone
Androidseemethyltestosterone
Andronateseetestosterone
angioedema, 243,264, 273
Angiostrongylus vasorum, 701
anonychia, 588
antibacterial soaps, 147
antibiotic resistance
client education, 146–147
emerging, 142–144
etiology, 143–144
historical background, 145–146
systemic treatment options, 151–152
transfer between species, 146, 727
antibiotics, 142–152
for acne, 159
for acral lick dermatitis, 233
for anal furunculosis/perianal fistula, 164, 168
cutaneous adverse reactions, 272,276–277,
279–280, 281
for eosinophilic granuloma complex, 354
for methicillin-resistant staphylococci, 151–152
for nocardiosis, 538
for otitis, 549, 550
for pemphigus/pemphigoid, 196
for pyoderma, 217–220,218–219
stewardship, 142, 143, 152
topical therapy, 142, 151
for vasculitis, 701
anti-cIL31 monoclonal antibody, 181
antifungal agents
for deep mycoses, 524–526
for dermatophytosis, 323–324
forMalasseziadermatitis, 483
for otitis, 549, 550
for paronychia/onychomycosis, 594
for sporotrichosis, 660–661
antihistamines
for atopic disease, 181
for cutaneous mastocytosis, 623
for cutaneous mucinosis, 624
for flea bites, 246
antimonial drugs, pentavalent, 462–463
Antirobeseeclindamycin
Antisedanseeatipamezole
antiseptics
for ear cleaning, 549
forMalasseziadermatitis, 483
for vasculitis, 483
see alsochlorhexidine
antithyroglobulin antibodies, 417, 420
Antivertseemeclizine
antiviral agents, 715
ant stings, 240–241, 243,262–263
apocrine cyst, 21
apoptosis, 39
Apoquelseeoclacitinib
Aquasol Aseevitamin A
Aquasol Eseevitamin E
Aristocortseetriamcinolone
armadillo protein, 188
Arquelseemeclofenamate
L-asparaginase, 369
asthenia, cutaneous, 64
Ataraxseehydroxyzine
atipamezole, 303, 750
Atopicaseecyclosporine
atopic disease (atopic dermatitis, AD), 173–182
adverse food reactions and, 287
clinical features, 176,182–186
diagnostics, 177–179
differential diagnosis, 177
etiology/pathophysiology, 10, 173–175
secondary pyoderma, 214, 220
signalment/history, 175–176
therapeutics, 179–181, 182
T-lymphoma pathogenesis, 365
atopic-like dermatitis, 173, 174
atrophy, epidermal
defined, 39
hyperadrenocorticism, 395,406–407, 410
atropine, 751
auranofin, 196, 751
aurothioglucose, 752
aurotrichia, acquired, of miniature schnauzers, 66
Australian cattle dog, 228, 732
Australian kelpie, 732
Australian shepherd dog, 732
cutaneous adverse drug reactions, 273
ivermectin sensitivity, 301, 551, 637
panniculitis, 563, 568
uveodermatologic syndrome, 692
Australian terrier, 432, 481, 732
autoimmune blistering diseases, 187–198
clinical features, 190–192,199–209
course and prognosis, 198
diagnostics, 194–195
differential diagnosis, 192–194
etiology/pathophysiology, 187–189
monitoring response to therapy, 197–198
signalment/history, 189–190
therapeutics, 195–197
autoimmune keratinization disorders, 435
autoimmune subepidermal blistering dermatoses
(AISBD), 187
Aveloxseemoxifloxacin
Axidseenizatidine